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Abstract Recent work has demonstrated that neurotransmit-
ters, signalling molecules primarily associated with the nervous
system, can have profound e¡ects on the skeleton. Bone cells
express a broad range of neurotransmitter receptors and trans-
porters, and respond to receptor activation by initiating diverse
intracellular signalling pathways, which modulate cellular func-
tion. Evidence of neuronal innervation in skeletal tissues, neuro-
transmitter release directly from bone cells and functional ef-
fects of pharmacological manipulation support the existence of a
complex and functionally signi¢cant neurotransmitter-mediated
signalling network in bone. This review aims to concisely sum-
marise our current understanding of how neurotransmitters af-
fect the skeletal system, focusing on their origin, cellular targets
and functional e¡ects in bone.
" 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Throughout life, old or damaged bone is periodically re-
moved and new bone is formed at discrete sites throughout
the skeleton. This regenerative process of bone remodelling is
dependent on the coupled formative and resorptive activities
of specialised bone cells, osteoblasts and osteoclasts, and
serves to prevent inappropriate changes in bone mass whilst
allowing precise structural adaptation necessary to meet the
varying physical and metabolic demands placed on the skel-
eton.
Intercellular communication plays a fundamental role in
regulating remodelling events, by controlling cell lineage com-
mitment, proliferation, di¡erentiation, function and apoptosis
of bone cells. A wide variety of cellular signals are implicated
in these processes including mechanical strain, systemic hor-
mones and locally released cytokines and growth factors. In
this review we focus on the emerging role of neurotransmitters
in bone and describe how these diverse signalling molecules
regulate bone formation and bone resorption through e¡ects
on osteoblasts and osteoclasts, and the activation of speci¢c
intracellular signalling pathways. Bone cells express a range of
functional neurotransmitter receptors and transporters includ-
ing those for glutamate, Q-aminobutyric acid (GABA), purines
and pyrimidines, 5-hydroxytryptamine (5-HT), catechol-
amines (dopamine, adrenaline and noradrenaline), and neuro-
peptides (vasointestinal peptide (VIP), substance P (SP), and
calcitonin gene-related peptide (CGRP)). Their expression and
activity provides direct evidence for a complex neurotransmit-
ter-mediated signalling network in bone (Fig. 1). We also
discuss neuronal innervation of the skeleton and describe
how bone cells themselves release neurotransmitters into the
bone microenvironment, which act as local autocrine and/or
paracrine signalling molecules, regulating the activity of
neighbouring cells. Finally we discuss how combining current
knowledge and resources of pharmaceutical companies could
provide fast-track treatment for a wide range of debilitating
bone disorders including osteoporosis.
2. Neuronal innervation of bone
The existence of nerve ¢bres in bone is well established,
although the heterogeneity and extent of innervation has
only recently become apparent. The presence of sensory and
sympathetic ¢bres has been demonstrated in the bone mar-
row, mineralised bone and periosteum [1^4], with bone mar-
row containing the greatest number of ¢bres per unit volume
[5]. The e¡ects of chemical and surgical denervation on skel-
etal function have been widely studied, but their contribution
to our understanding of neurotransmitters in bone is less
clear. Mechanical loading is a potent stimulator of osteogen-
esis, which is impaired by lack of movement caused by some
types of denervation. As such, it is di⁄cult to determine
whether changes in bone remodelling result from direct inhi-
bition of neurotransmitter signalling or from indirect e¡ects
on mechanical forces acting on the skeleton. However, skel-
etal phenotypes observed in some denervated bones suggest
that changes in pathology cannot be explained solely by dis-
use. For instance surgical and pharmacological sympathec-
tomy has been demonstrated to increase the number of osteo-
clasts and bone resorption in inner ear bones, which are not
exposed to mechanical stimulation [107]. Sympathetic nerves
innervating bone have recently been directly linked to the
control of osteoblast activity. These are stimulated via a hy-
pothalamic relay involving leptin and release noradrenaline
into the bone microenvironment, activating L2-adrenergic re-
ceptors expressed by osteoblasts, inhibiting their osteogenic
activity [7]. Acid-sensing ion channels have also been identi-
¢ed on sensory ¢bres innervating mineralised bone which may
be involved in sensing low pH brought about by resorbing
osteoclasts [8,9].
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3. Glutamate
Mechanisms of glutamate transport and release, receptor
expression and downstream signalling events have been iden-
ti¢ed in bone (reviewed in [10]). Interest in the ¢eld was ¢rst
stimulated by the ¢nding that the gene encoding the gluta-
mate/aspartate transporter (GLAST/EAAT-1), previously be-
lieved to be expressed only in the central nervous system
(CNS) [11], was expressed by osteoblasts and newly embedded
osteocytes [12]. Other glutamate transporter proteins have
also been identi¢ed in bone, including GLT-1/EAAT-2, which
appears to be expressed by mononuclear bone marrow cells
[12].
Subsequent studies, which focused on determining expres-
sion of glutamate receptors by bone cells, identi¢ed members
of the ionotropic family of ligand gated ion channels (K-ami-
no-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), N-
methyl-D-aspartate (NMDA) and kainate receptor subtypes)
and metabotropic G protein-coupled receptors. NMDA re-
ceptors are the best-characterised glutamate signalling recep-
tors in skeletal tissues and their expression has been demon-
strated on osteoblasts, osteoclasts and megakaryocytes in
vitro and in vivo [13^17]. In the CNS, NMDA receptors exist
as heterotetramers assembled from the NMDA receptor (NR)
subunits NR1, NR2A^D, NR3A and B [18]. Although evi-
dence of NR1 expression on osteoblasts, osteocytes and os-
teoclasts is convincing, disparity exists with regard to expres-
sion of the regulatory NR2 subunits. Hinoi and co-workers
describe expression of NR2D, but not NR2A, B or C in rat
calvarial osteoblasts [19], whilst others report expression of
NR2C but not NR2A, B or D [20] or NR2A, B and D but
not C [21]. Potential explanations for these di¡erences exist,
based on di¡ering detection methods and sample sources,
although a de¢nitive answer remains elusive. As receptor com-
position signi¢cantly alters conductivity and sensitivity, it
would seem likely that di¡erent receptor stoichiometry would
exist on di¡erent bone cells, allowing them to respond di¡er-
entially to common signals.
Glutamate receptors expressed by bone cells have similar
functional properties to those found in the CNS. On ago-
nist-mediated receptor activation, NMDA receptor channel
currents and increases in intracellular calcium have been de-
tected in bone cells with primary osteoblasts and osteoclasts
exhibiting electrophysiological characteristics very similar to
neuronal cells [20,22]. Indeed in primary rat osteoblasts,
NMDA receptor activity is regulated by co-expressed metab-
otropic receptors, which is directly comparable to central glu-
tamatergic synapses [20].
Antagonism of NMDA receptors has been demonstrated to
inhibit both bone formation and resorption in vitro [15,23].
These e¡ects appear to be mediated through impaired cell
di¡erentiation rather than proliferation or activity of mature
cells [15,24,25]. NMDA receptor antagonism has also been
shown to attenuate the DNA binding activity of the key tran-
scription factor core binding factor-1 (Cbfa-1), which is re-
quired for osteoblast di¡erentiation, and inhibit osteoclast
formation in coculture assays of bone resorption [24]. In con-
trast, AMPA receptors appear to play a role in osteoblast
lineage determination, as AMPA receptor blockade promotes
adipogenesis in bone marrow stromal cell cultures at the ex-
pense of osteoblastic di¡erentiation [26].
Studies on the expression and function of glutamate recep-
tors in bone raised important questions regarding the source
of agonist required for receptor activation. Neuronal innerva-
tion of bone by glutamate-containing peripheral nerves has
recently been demonstrated by immunohistochemistry [27].
Signi¢cantly, osteoblasts have been demonstrated to express
components of neuronal presynaptic machinery required for
glutamate release in the CNS, including molecules involved in
synaptic vesicle packaging, targeting and fusion [28]. These
also include the vesicular glutamate transporter VGLUT1,
whose expression in the CNS is both necessary and su⁄cient
to confer glutamate release characteristics on non-glutamater-
gic neurones [29]. More compelling evidence for an osteoblas-
tic source of glutamate is provided by studies demonstrating
regulated and spontaneous glutamate exocytosis from osteo-
blasts, prevention of which inhibits cell survival and di¡er-
entiation [6,30].
Fig. 1. E¡ects of neurotransmitters in the bone microenvironment. Schematic representation detailing the putative functions of neurotransmit-
ters involved in the regulation of bone remodelling and megakaryocytopoiesis. Although the origin of several transmitters is still unclear, bone
and marrow are highly innervated with peripheral nerves, which likely contribute to local neurotransmitter release. Abbreviations: ATP, adeno-
sine triphosphate; CGRP, calcitonin gene-related peptide; CNS, central nervous system; GABA, Q-aminobutyric acid; NA, noradrenaline; VIP,
vasointestinal peptide.
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Glutamate signalling in bone does not exclusively involve
osteoblasts and osteoclasts, and includes bone marrow mega-
karyocytes, whose primary function is the production and
release of functional platelets. Megakaryocytes express NR1,
NR2A and NR2D subunits and antagonism of receptor ac-
tivity inhibits di¡erentiation of cell lines and human primary
megakaryocytes in vitro [16,17]. Cells incubated with antago-
nist also fail to produce proplatelet structures, and lack the
cytoplasmic characteristics and organelles essential for the
production of functioning platelets [17].
4. GABA
GABA is the principal inhibitory neurotransmitter in the
CNS synthesised from glutamate by glutamic acid decarbox-
ylase. GABA mediates its actions through ionotropic
(GABAA and GABAC) or metabotropic (GABAB) receptors.
Activated ionotropic receptors conduct Cl3 ions and the me-
tabotropic receptors transduce signals through the G1/G0
family of G proteins. GABA receptors have been identi¢ed
in a range of peripheral tissues, including testes, lung, liver,
gastrointestinal tract and mammary gland [31]. Recent evi-
dence also suggests that GABA may act as a trophic factor,
with the ability to modulate cell proliferation, di¡erentiation
and survival during neuronal development [32]. Following the
identi¢cation of functional glutamate receptors in bone cells,
Fujimori and co-workers [33] determined the expression and
activity of di¡erent GABA receptors in rodent primary and
clonal osteoblastic cells, identifying two GABAB receptor
splice variants (GABABR-1a and GABABR-1b). Exposure
to the GABABR agonist baclofen inhibited forskolin-induced
cAMP formation in primary osteoblasts and reduced alkaline
phosphatase activity and calcium accumulation in MC3T3-E1
cells, over 28 days in culture. Although more work is required
in this area, these initial studies at least suggest that both
glutamate and GABA signalling mechanisms may co-exist
within the bone microenvironment to mediate autocrine and
paracrine signalling in a manner analogous to the excitatory/
inhibitory neuronal network in the CNS.
5. Purines and pyrimidines
Receptors to purines and pyrimidines have been identi¢ed
and classi¢ed according to their responses to the physiological
agonists: adenosine (P1 receptors), ATP, ADP, UTP and
UDP (P2 receptors) and adenine dinucleotides (P4 receptors)
[34,35]. P2 receptors are further subdivided on the basis of
molecular structure, pharmacology and signal transduction
mechanisms into P2X (ligand-gated ion channels) and P2Y
(G protein-coupled receptors). To date ligand binding studies
and molecular cloning have identi¢ed four P1 adenosine re-
ceptors (A1, A2A, A2B, A3), seven P2X receptors (P2X17)
and ¢ve P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11)
[34].
Pharmacological evidence exists to support the existence of
A2 adenosine receptors on osteoblasts derived from mouse
calvaria, which are capable of inducing cAMP formation.
Adenosine has also been reported to be mitogenic for
MC3T3-E1 cells and has been demonstrated to act synergis-
tically with platelet-derived growth factor to induce DNA syn-
thesis [36,37].
To our knowledge expression of P4 receptors sensitive to
adenine dinucleotides has not been identi¢ed on bone cells
although studies have identi¢ed expression of numerous P2
receptors including P2X2, P2X5, P2X7, P2Y1, P2Y2, P2Y4
and P2Y6 by osteoblasts, P2X1, P2X2, P2X4 P2X5, P2X6,
P2X7, P2Y1, P2Y2; P2Y4, P2Y6 and P2Y11 by osteoclasts,
and P2X2, P2X5, P2Y1 and P2Y2 by chondrocytes using a
variety of detection techniques and range of tissue samples
[38]. Extracellular nucleotides acting via P2Y1 and P2Y2 re-
ceptors have been demonstrated to increase inositol 1,4,5-tris-
phosphate production and transiently increase intracellular
calcium [39^41] and ATP has been demonstrated to dose-de-
pendently inhibit bone formation by osteoblasts in vitro
[42,43]. Mitogenic e¡ects of ATP and synergistic actions
with growth factors on osteoblast proliferation have also
been reported [38]. More recently P2X receptors have been
implicated in the control of osteoblast apoptosis (P2X7) and
propagation of intercellular calcium signals between osteo-
blasts (P2Y2), and between osteoblasts and osteoclasts
(P2X7) [44^46].
Osteoblastic P2Y receptors (P2Y1, P2Y2 and P2Y ADP) are
also implicated in signalling cross-talk with other pathways
important in regulating bone cell function. Activation of P2
receptors has been demonstrated to potentiate the actions of
parathyroid hormone (PTH), a principal regulator of bone
formation and bone resorption, increasing inositol trisphos-
phate generation and intracellular calcium concentrations in
rat osteoblastic cells [47]. P2 receptors also synergise with
PTH to upregulate expression of the transcription factor c-
fos, providing a mechanism of regulating osteoblastic gene
expression [48].
Electrophysiological studies are consistent with expression
of functional P2X and P2Y receptors by disaggregated rabbit
osteoclasts with characteristic properties of P2X4, P2X7 and
P2Y1 [49^51]. Extracellular ATP has been shown to stimulate
bone resorption by cells derived from human osteoclastoma
and although P2Y2 receptors were originally proposed to me-
diate these e¡ects, subsequent investigations demonstrated lit-
tle e¡ect of P2Y2 receptor agonists [52]. ADP, acting via the
P2Y1 receptor, has been reported to stimulate osteoclast for-
mation and bone resorption in numerous assays of osteoclast
activity [53]. A potential role for the acid-sensitive P2X2 re-
ceptor in stimulating bone resorption has also been suggested
from observations that the pro-resorptive e¡ects of ATP are
ampli¢ed at low pH [54]. At a molecular level, ATP increases
intracellular calcium through two distinct mechanisms in os-
teoclasts: P2Y-mediated, thapsigargin-sensitive, calcium re-
lease from intracellular stores and in£ux of extracellular cal-
cium through P2X7 receptors [51,55,56]. Roles for P2X7
receptors in the fusion of osteoclast progenitors and apoptosis
of mature osteoclasts have also been suggested [38]. It has
been proposed that at least some of the pro-resorptive e¡ects
of extracellular nucleotides may be mediated indirectly by
osteoblasts through increased expression of the osteoclast dif-
ferentiation factor, receptor activator of NF-UB ligand or re-
lease of pro-resorptive cytokines [57].
In addition to osteoblasts and osteoclasts, P2 receptors are
also implicated in the control of chondrocyte function. Acti-
vation of P2Y2 receptors has been demonstrated to elevate
intracellular calcium and enhance basic ¢broblast growth fac-
tor-induced proliferation of sheep chondrocytes [58].
Although peripheral nerves innervating bone provide one
potential source of nucleotides in the bone microenvironment,
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local release from osteoblasts, chondrocytes and megakaryo-
cytes has all been described [59^61]. Other sources include
nucleotides released as a consequence of cell death or agonists
generated by interconversion through the actions of ecto-nu-
cleoside diphosphokinase expressed by osteoblasts [59].
6. 5-HT
Expression of 5-HT receptors (5-HT1A, 5-HT1D, 5-HT2A, 5-
HT2B) and speci¢c 5-HT transporter has been demonstrated
in primary rat osteoblasts and clonal osteoblastic cells lines in
vitro [62]. These transporters are functional and their activity
increases during osteoblast di¡erentiation in vitro. Expression
of 5-HT2B receptors has also been shown in chick osteoblasts,
osteocytes and periosteal ¢broblasts, a cell population con-
taining osteoblast progenitor cells [63]. In functional studies,
5-HT has been reported to potentiate PTH-induced increases
in activity of the AP-1 transcription factor complex and in-
crease proliferation of periosteal ¢broblasts. 5-HT receptor
activation is also implicated in regulating mechanotransduc-
tion by osteoblasts, inhibiting the production of nitric oxide in
response to mechanical strain [62,63]. These data provide
some evidence for a functional serotoninergic signalling sys-
tem in bone comprised of essential cellular mechanisms re-
quired to respond to and recycle 5-HT.
7. Catecholamines
The catecholamines include dopamine, adrenaline (epineph-
rine) and noradrenaline (norepinephrine), which are formed
from tyrosine following a common synthetic pathway. Adren-
aline and noradrenaline exert their e¡ects through interaction
with di¡erent G protein-coupled K- and L-adrenergic recep-
tors (ARs). All ARs are members of the G protein-coupled,
seven transmembrane domain containing superfamily of re-
ceptors, and use a variety of intracellular signalling mecha-
nisms to modulate cellular function. In early studies in bone it
was shown that the L-adrenergic agonist isoproterenol could
stimulate adenylate cyclase in clonal rat osteoblast-like cells
[64,65], in a manner sensitive to dexamethasone and retinoic
acid exposure [66,67]. In the mouse preosteoblastic cell line
MC3T3-E1, adrenaline was shown to increase prostaglandin
E2 (PGE2) production [68], whereas noradrenaline has been
reported to enhance cAMP formation in MC3T3-E1 cells, as
well as ROS17/2.8, UMR-106-01 and SaOS-2 osteoblastic
cells [69,70]. It was later demonstrated by reverse transcription
polymerase chain reaction (RT-PCR) analysis and receptor
binding studies that the L2AR subtype, but not L1AR, was
expressed by ROS17/2.8 cells [71]. However, Northern blot
analyses have identi¢ed L1AR and L2AR expression in several
osteoblast-like cell lines including SaOS-2, TE-85, MG-63
(L2AR only) and OHS-4 (L1AR only) [72]. These authors
also demonstrated that speci¢c activation of L2ARs induced
immediate early c-fos expression in SaOS-2 cells [72]. Cate-
cholamines have also been shown to enhance DNA synthesis
and increase alkaline phosphatase activity in MC3T3-E1 cells,
although without a¡ecting collagen synthesis or osteocalcin
production, with pharmacological evidence suggesting that
these e¡ects were mediated through K1ARs [73]. Reports
from the same group suggest that mitogen-activated protein
(MAP) kinases are essential intracellular mediators of the ac-
tions of adrenaline on MC3T3-E1 cells, with the extracellular
signal-regulated kinase pathway mediating proliferative re-
sponses and the p38 MAP kinase pathway inducing increased
alkaline phosphatase activity [74]. In addition, adrenaline has
been shown to stimulate sodium-dependent inorganic phos-
phate transport in MC3T3-E1 cells [75].
More recently using RT-PCR, it has been suggested that
activation of L-adrenergic signalling in MC3T3-E1 cells causes
increased expression of interleukin (IL)-6, IL-11, PGE2,
RANKL and OPG, which results in increased osteoclastogen-
esis [76,77], and application of noradrenaline and isoprotere-
nol has been shown to stimulate bone resorption in organ
cultures [71]. The importance of adrenergic signalling in
bone remodelling has been demonstrated in vivo. Application
of the non-selective antagonist of L2ARs, propranolol, en-
hanced endochondral bone formation rates during the repair
of excisional defects in surgical rat models as well as increas-
ing torsional strength in non-surgical models [78]. In vivo
administration of clenbuterol, a L2AR agonist, has also been
reported to inhibit the reduction in bone mineralisation in-
duced by sciatic neurectomy [79] ; however, it was unclear
from this study whether the observed e¡ects could have
been attributed to anabolic actions of the L2AR agonist on
muscle. Later reports indicated that clenbuterol inhibited lon-
gitudinal bone growth [80] and reduced bone mineral density
when administered to rats undergoing di¡erent exercise re-
gimes [81].
8. Acetylcholine
Acetylcholine (ACh) is synthesised by the action of choline
acetyltransferase on acetyl-CoA and transmits nerve impulses
at cholinergic synapses and motor end plates of neuromuscu-
lar junctions. Following vesicular release, ACh binds to either
ionotropic (Naþ and Kþ gating) nicotinic ACh receptors
(AChR) or metabotropic, G protein-coupled muscarinic
AChR to initiate downstream signalling events. Signalling is
terminated by acetylcholinesterase (AChE), which hydrolyses
ACh into choline and acetate.
We have found little evidence to suggest that muscarinic
AChRs are expressed by bone cells [82], although one study,
using in situ hybridisation to investigate the distribution of
nicotinic AChRs in the inner ear of rats, did identify K9
AChR mRNA expression in developing osteoblast and/or
chondrocytes in the cochlear capsule [83]. Others have identi-
¢ed expression of K7 and K4 nicotinic AChR mRNAs in
periosteal cells and human primary bone [84,85]. Nicotine
has been reported to regulate osteoblast proliferation and in-
duce expression of the AP1 transcription factor complex and
the bone matrix protein osteopontin. These e¡ects are at least
partly sensitive to the nicotinic receptor antagonist D-tubocur-
arine, consistent with a speci¢c receptor-mediated a¡ect [85].
Nicotine has also been reported to inhibit the formation of
osteoclasts and bone resorption in osteoblast/mononuclear
cell cocultures although it is unclear whether these e¡ects
are directly or indirectly mediated, or indeed whether they
involve activation of speci¢c receptors [86].
We and others have recently shown that AChE is expressed
by osteoblasts and can regulate cellular activity in bone
[82,87]. AChE expression has often been identi¢ed in the ab-
sence of any clear cholinergic signalling and there is growing
evidence indicating that AChE has multiple non-cholinergic
functions in a range of tissue types [88]. In bone, AChE ap-
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pears to be able to augment osteoblast adhesion and di¡er-
entiation and several putative binding sites for osteogenic fac-
tors have been identi¢ed in the human AChE promoter region
[82,87]. These include consensus binding motifs for Cbfa-1 as
well as vitamin D receptor and oestrogen receptor binding
elements. The complexity of intrinsic cholinergic-like signal-
ling mechanisms in bone tissue is still unclear, but these early
studies do suggest that the role of AChE in bone remodelling
and development warrants further investigation.
9. Neuropeptides
Nerves immunoreactive to VIP, SP, CGRP and neuropep-
tide Y (NPY) have been identi¢ed in bone innervating the
periosteum, vasculature, growth plate and marrow, implicat-
ing a complex role for neuropeptides in the control of bone
cell function [89].
9.1. VIP
Based on pharmacological studies and cAMP assays, ex-
pression of VIP (VIP1 and VIP2) and CGRP receptors has
been demonstrated on osteoblasts [70,90,91] and their expres-
sion, along with NPY, has subsequently been con¢rmed by
RT-PCR [92,93]. VIP increases intracellular calcium concen-
trations in osteoblasts and stimulates PGE2 production in a
range of human bone cells [90,94], providing evidence for
functional coupling of receptor activation to intracellular sig-
nalling pathways. In functional assays, VIP has been demon-
strated to increase alkaline phosphatase activity, regulate ex-
pression of a number of osteoblastic markers and stimulate
mineralisation in vitro, consistent with an anabolic e¡ect [95].
VIP has also been reported to both inhibit and stimulate bone
resorption, through a direct e¡ect on mature osteoclasts and
indirect e¡ects on RANKL expression by osteoblasts ([95] and
references therein). Thus VIP can be considered to have a
pleiotropic e¡ect on bone, regulating both bone formation
and bone resorption.
9.2. SP
SP receptors have also been identi¢ed by immunohisto-
chemistry on osteoclasts [96] and their activation has been
demonstrated to stimulate calcium in£ux and bone resorption
in vitro [97]. Expression of SP receptors by osteoblasts is less
clear and requires further clari¢cation in light of con£icting
reports con¢rming and refuting their presence [92,96].
9.3. CGRP
Like VIP, CGRP also has pleiotropic e¡ects on bone, stim-
ulating bone formation and inhibiting bone resorption. Acti-
vation of osteoblastic CGRP receptors has been demonstrated
to increase cAMP formation [98] and stimulate the prolifer-
ation of osteoblasts in vitro [99]. Transgenic mice overexpress-
ing osteoblast-derived CGRP under the control of the osteo-
calcin promoter have a skeletal phenotype consistent with
anabolic e¡ects on bone [100], furthermore, systemic admin-
istration of CGRP partially reverses the osteoporotic pheno-
type of ovariectomy [101]. More recently calcitonin/CGRP
knockout mice have been generated by heterologous recombi-
nation, which, like CGRP-overexpressing mice, exhibit an
anabolic phenotype. These mice are also protected against
ovariectomy and are more sensitive to PTH-stimulated bone
resorption [102]. CGRP has also been demonstrated to inhibit
bone resorption in vitro and in vivo, raising the possibility
that at least some of the stimulatory e¡ects of CGRP on
bone mass may result from decreased bone resorption
[103,104].
10. Conclusions
It is clear that neurotransmitters have profound e¡ects on
bone, in£uencing the di¡erentiation, proliferation, activity
and apoptosis of osteoblasts and osteoclasts. As such, manip-
ulation of these signalling pathways o¡ers real therapeutic
potential for the treatment of a wide range of bone disorders
characterised by inappropriate and excessive changes in bone
formation and/or bone resorption. For example, it has been
suggested that osteoporosis aetiology results from an age-re-
lated failure in the adaptive osteogenic responses of bone cells
to mechanical stimulation which plays an important role in
maintaining adequate bone mass [105]. There is evidence to
suggest osteoblasts use glutamate as a signalling molecule to
perceive, record and respond to these changes through a
mechanism similar or identical to neuronal long-term poten-
tiation, a process of synaptic plasticity implicated in long-term
memory formation in the CNS [106]. If this hypothesis and
that of memory formation in bone are true it may be possible
to pharmacologically prime the skeleton to mimic, retrieve or
enhance the osteogenic response of exercise for the treatment
of osteoporosis. To this end it is noteworthy that thousands of
compounds line the shelves of pharmaceutical companies, de-
veloped for the treatment of central disorders and rejected on
the basis of their inability to cross the blood^brain barrier.
These compounds, used to treat ‘peripheral’ bone disorders,
would lack any unwanted central side e¡ects, and may there-
fore provide a ‘fast-track’ pharmaceutical approach for the
treatment of bone disorders.
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